BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...regulatorENaC - Epithelial sodium channelTMEM16A (AN01) - Anoctamin 1 calcium activated chloride channel Paul Bonanos Enterprise Therapeutics Ltd. Anoctamin 1 calcium activated chloride channel (TMEM16A) (ANO1) ETD002...
BioCentury | Jun 20, 2019
Distillery Techniques

TMEM16A as a marker for survival in pancreatic cancer

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling A study from Lily Yeh Jan and Yuh Nung Jan at UCSF suggests that tumor levels of TMEM16A could help predict survival in pancreatic cancer patients, and...
BioCentury | Apr 13, 2018
Financial News

Enterprise raises £29M series B

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and...
BioCentury | Apr 12, 2018
Financial News

Versant, Novartis Venture lead £29M round for Enterprise

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and existing investors Epidarex...
BioCentury | Apr 12, 2018
Finance

Enterprise engages

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round. Versant Ventures and Novartis Venture...
Items per page:
1 - 5 of 5